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A B S T R A C T
BACKGROUND: Aortic arch stenting appears to be a debatable topic among cardiac 
surgeons, cardiologists and interventional radiologists. During the last decade a va-
riety of products of endovascular treatment has been applied either to open heart 
surgery or to hybrid management of aortic arch pathology. In general, fenestrated, 
bare and multilayer stents are separate issues to be investigated, in contrary to covered 
stents which seem to gain their place in cardiovascular operations. Additionally new 
sophisticated devices and methods derived from current literature, e.g. Djumbodis, 
E-xl, BOS, Frozen elephant trunk (EVITA OPEN), & Cardiatis, promote the idea of 
hybrid treatment of aortic arch pathology.
AIM, METHODS & RESULTS: The primary purpose in our presentation is to discuss 
several aspects of aortic arch stenting and to investigate the possibility of perform-
ing less invasive operations by the use of evolutionary facilities in order to define the 
spectrum of indications and to improve decision making. Currently there is no ad-
equate evidence (level A or B) to develop guidelines for the management of acute aor-
tic syndromes and thoracic aneurysms. According to several articles in the literature, 
endovascular interventions and hybrid repairs seem to approach or even to decrease 
the rate of mortality and morbidity in comparison to open surgical procedures and 
medical treatments. On the other hand, many reports in current literature indicate 
that conventional aortic arch surgery or conservative treatment are superior to stent-
ing, thus creating a foggy field for a well established decision making.
CONCLUSION: Thus, for endovascular or hybrid treatment of aortic arch pathology, 
these new technological entities in pair to previous applied methods should be studied 
further in multicenter prospective randomized trials in order to create a safe treat-
ment environment.
I N T R O D U C T I O N
Aortic arch stenting appears to be a debatable topic among cardiac surgeons, car-
diologists and interventional radiologists. Over the last decade a variety of products of 
endovascular treatment has been applied either to open heart surgery, endovascular 
or hybrid management of aortic arch pathology.
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ABBREVIATIONS
DHCA= deep hypothermic circulatory 
arrest
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O P E N  S U R G I C A L  R E S U L T S
Until recently the only available therapeutic option for the 
aortic arch pathology was the traditional open surgical pro-
cedure with cardiopulmonary bypass and deep hypothermic 
circulatory arrest (DHCA). In the last decade many efforts 
from scientists aim to import endovascular methods and treat-
ments in the realm of the synchronous cardiac surgeon and 
cardiologist. Does the conventional open surgery need the 
endovascular component of treatment to be improved?
First of all we have to appreciate the results of classic 
open surgery. The majority of studies in aortic arch surgery 
report mortality between 6.3-16.5% and an incidence of stroke 
between 6.7-18%. Especially the incidence of stroke depends 
on the duration of circulatory arrest and is defined at 13.8% 
if you have less than 30 min of DHCA and 37.9% if you have 
more than 30 min of DHCA.1
Let’s see the surgical results in a contiguous area. What is 
happening if the aortic pathology extends from the arch to the 
descending aorta? Really impressive results have published by 
Kouchoukos NT et al.2 They treated 51 patients with chronic 
expanding thoracic aortic dissections (48 type A, 3 type B 
with proximal extension) with a single procedure using a bi-
lateral anterior thoracotomy, hypothermic circulatory arrest, 
and reperfusion of the arch vessels first, to minimize brain 
ischemia. Hospital mortality was 3.9%. No patient sustained 
a stroke. The conventional approach using the elephant trunk 
technique (two-stage procedure) has been studied in many 
centers for many years. Again from the U.S.A, Etz CD et al 
3 reported mortality of 6.5% for the first stage and 7.5% for 
the second stage. The overall cumulative survival, including 
patients dying before or without stage two, was 69% after 1 
year and 55% after 5 years.
In general, open procedures are well established and their 
results are satisfactory. But can we achieve even better results 
than those obtained via the open procedures? Zipfel et al 4 
(Deutsches Herzzentrum Berlin) published a case report 
which concerned a 22-year-old man with Marfan’s syndrome 
and ascending aorta aneurysm with type B dissection, and 
an abdominal aorta aneurysm. On January 1993, the patient 
underwent replacement of ascending aorta and aortic root 
(Cabrol technique). After 2 months he was submitted to re-
placement of the descending aorta, and after 4 months to re-
placement of the abdominal aorta with concomitant aorto-iliac 
bypass. All the surgical procedures were completely successful. 
Unfortunately, 3 months later the patient was dependent on 
biventricular assist device which eventually bridged him to 
heart transplantation. The conduction of this multifold sur-
gical course was completely successful but the patient would 
have died without a new heart. Thus conventional surgery 
has its endogenous problems which derive from the invasive 
character of the procedure and from the aggressive manner 
the patient is managed. So at least we have to appreciate and 
estimate the new endovascular modalities.
E N D O V A S C U L A R  T R E A T M E N T  O F 
A O R T I C  A R C H
C O V E R E D  S T E N T S
Which are the current endovascular treatments which are 
available and have been used by many physicians? Aortic arch 
stenting following aortic arch debranching (extra-anatomic 
bypasses) is an applied method in many centers worldwide, 
especially, for high risk patients. Substantially this is a hybrid 
method which combines both surgical (debranching- extra 
anatomic bypass) and endovascular treatment (stent grafting) 
with covered stents. Follow up studies of such extra-anatomic 
bypasses have demonstrated patency rates of 88% at 3 years 
and 84% at 5 years.1 The academic teaching hospital Hanau 
from Germany (Schumacher et al5) reported that the overall 
perioperative 30-day mortality was 20% in high risk patients 
who were excluded by cardiac surgeons as ineligible for con-
ventional arch repair. Melissano et al6 operated on 42 patients 
and published their results. They report mortality at 30 days 
of 6.3%, stroke 3.1%, and paraparesis or paraplegia 3.1% 
including not only high risk patients.
F E N E S T R A T E D  A N D  B R A N C H E D  S T E N T S
An alternative which has been proposed to address this 
issue is fenestration and branch technology. This technology 
has been applied to thoracoabdominal aneurysms widely, 
but there is no application in aortic arch pathology with the 
exception of very few cases worldwide, which concern partial 
or distal arch pathology and not the entire arch. Also there 
exist few experimental data in animals and cadavers.
M U L T I L A Y E R  S T E N T
A big issue in current era is the new technological develop-
ment which is called multilayer stent (cardiatis). This endovas-
cular “gadget” claims that it slows and laminates blood flow 
inside the aneurysm, minimizing possibilities of aneurysm 
rupture and allowing an organized thrombus to form. The 
most important and exciting part is that it allows and preserves 
blood flow to the branches. This aneurysm repair system has 
received CE-mark approval in Europe for peripheral artery 
disease. The first treated patient was a 78-year-old male in 
Greece who underwent a minimally invasive endovascular 
procedure that placed a cardiatis stent to treat a large renal 
artery saccular aneurysm with side branches by Michel Henry 
and Antonios Polydorou.7 The 7-month follow-up angiogram 
confirmed reduction in aneurysm size, collapse of the aneurys-
mal sac and preservation of flow in vital collateral circulation 
with open and functional branches. The same success had a 
popliteal aneurysm treated the same way in Greece by Poly-
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dorou (personal communication). A month ago the same stent 
was used with success to treat a thoracoabominal aneurysm 
by Polydorou and Kokotsakis in a patient who was enrolled in 
a protocol investigating the use of this type of stent (personal 
communication). The future will show if this modality proves 
to be a long term durable and effective technique.
U N C O V E R E D  S T E N T S
A big chapter of aortic arch pathology is acute aortic 
syndromes including dissections. For this portion of aortic 
diseases two new sophisticated devices are now available to 
be added in our therapeutic armamentarium: the Djumbodis 
dissection system from Saint Come and the E-XL device from 
Jotec. These new modalities are uncovered stents which can 
be placed in the aortic arch in combination with open surgical 
replacement of the ascending aorta mostly in cases of acute 
aortic dissection type A. The purpose of this hybrid manage-
ment is to reduce the invasiveness of the whole procedure 
and consequently the attendant morbidity and mortality. A 
published abstract by Ius et al8 (23rd EACTS Annual Meet-
ing, Vienna Austria, October 2009) concludes that placement 
of this type of stents seems to obtain, early postoperatively, 
a more favourable, albeit not significant, ratio between de-
scending aorta and true lumen. Another study from Toulouse 
by Leobon et al9 indicates that the use of these devices can 
achieve reduction in number of perfused false lumen of aortic 
arches, more often stented, than for descending aortas and 
for dissected and stented segments versus dissected unstented 
segments.
B R A N C H E D  O P E N  S T E N T  G R A F T I N G 
T E C H N I Q U E
The same rationale of reduced invasiveness and hy-
brid management has the branched open stent grafting 
technique, which has been described by Shimamura et al10 
from Osaka University Graduate School of Medicine in 
Japan. According to this technique, home-made branched 
endoprothessis reconstructs the descending aorta and aortic 
arch with its cervical branches, simultaneously in a single 
sort circulatory arrest period through the opened proximal 
aortic arch thus, completing total arch repair by the same 
aortic incision line as the hemiarch repair. The Japan group 
performed this technique in 69 cases and reports 30-day 
mortality of 4.3%, incidence of stroke 5.8% and of spinal 
cord injury 2.9%. The survival rate was 90.9%, 88.8% and 
88.8% the first, second and third year respectively. A 5% 
of the cervical stent grafts showed endo-leakage and were 
treated by additional endovascular repair. To the afore-
mentioned stents one can add the E-Vita open plus (frozen 
elephant trunk) and the E-Vita proximal endoprotheses 
which are uncovered along the major curve of the arch and 
covered along the minor curve which allows blood flow to 
the branches of aortic arch.
D I S C U S S I O N
It becomes clear from the aforementioned that thoracic 
endovascular therapies are unlimited. For almost every aortic 
pathology, there exists an endovascular or hybrid approach 
which promises less invasiveness. On the other hand, even 
in the most widely applied endovascular field which is the 
descending thoracic aorta, there is no level A or B evidence 
(results from prospective randomized trials) to compare 
medical therapy with surgical intervention, or the results of 
open procedures with endovascular stent graft procedures as 
this is noted in the STS Expert Consensus Document. Pos-
sibly Dietrich from the Arizona Heart Institute was accurate 
when he was saying in a lecture held in Athens 3 years ago, 
that practically there is no consensus on these issues. Let’s 
analyse some studies and some important aspects.
Recently, Buz et al11 published a retrospective study of 74 
patients with acute traumatic aortic rupture. Among them, 
35 underwent surgical repair and 39 underwent endograft 
implantation. Hospital mortality was 20% in the surgical 
group and 7.7% in the endovascular group. The mean age of 
the patients was 36 years. So, is the endovascular treatment 
the winner? What happens with the long term durability of 
these stents? Stents have been designed to have a durability of 
ten years based on ISO stress testing. The majority of patients 
with traumatic aortic rupture are young people who will live 
30 to 60 years with their implanted stent. On a different note, 
impressive results come from a study of Kieffer et al12 from 
Paris who repaired descending thoracic aortic aneurysms. A 
total of 52 patients underwent endovascular stent graft repair 
(group 1). Endovascular repair was carried our exclusively in 
high surgical risk patients in whom preoperative spinal cord 
arteriography usually demonstrated that the origin of the 
Adamkiewicz was located outside the covered zone. Another 
121 patients underwent open surgical repair. Hospital mor-
tality was 15.4% for the endovascular group and 5% for the 
surgical group.
The majority of published reviews of thoracoabdominal 
aneurysm repairs via endovascular approach report results 
which are favourable compared to open surgery in high risk 
patients. Unfortunately, we do not have long term results, 
which are necessary to evaluate specific complications such 
as migration, material fatigue and component separation, 
that can result in loss of visceral branches and thus in an 
increased delayed morbidity and mortality. Consequently, 
we do have available technological developments, modali-
ties, techniques and “smart” devices but we do not have basic 
principles on which we would consolidate an applied evidence 
based medicine. A potentially basic principle which concerns 
aortic pathology is that false lumen patency predisposes for 
late aorta related events. However, Juvonen et al13 conclude 
that neither the presence of a persistently patent false lumen 
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nor a large abdominal aortic diameter appears to increase 
the risk of rupture. On the other hand, Marui et al14 state that 
the degree of fusiform dilatation of the proximal descending 
aorta, a patent false lumen and a large aortic diameter are the 
predominant predictors of late aortic events in patients with 
type B acute aortic dissection.
The majority of reports contemplate the patent false lu-
men as the main culprit for the progress of the disease. This 
was the rationale on which the planning and the conduction 
of the INSTEAD trial was based. In this study, Nienabar et 
al15 investigated the outcome after endovascular aortic repair 
(EVAR) in uncomplicated acute type B dissections. Although 
aortic remodeling, with true lumen recovery and false lumen 
thrombosis, occurred in 91.3% of patients with EVAR versus 
19.4% of those who received medical treatment, the trial failed 
to prove any 2-year survival benefit for the EVAR group.
Undoubtedly, endovascular treatment is the future, is at-
tractive, sometimes easier and faster but it is not a panacea 
and has its own limitations. It necessitates intensive follow 
up for life and often requires re-interventions. Open repairs 
seem to remain durable over the long term and do not require 
multiple re-interventions. Possibly the issue is similar to the 
debate between CABG and coronary artery stenting. The 
accessibility and the convenience of endovascular modality 
should not impel physicians to overuse. Endovascular treat-
ment presupposes wisdom judgment. The STS Expret Consen-
sus Document on the treatment of descending thoracic aortic 
disease using endovascular stent grafts underlines: “Elderly 
patients who have multiple additional medical conditions, 
that handicapped their quality of life, because stent grafting 
does not improve quality of life in asymptomatic patient, the 
logic of proceeding with an invasive intervention to prevent 
aneurysm rupture in patients who are approaching the end of 
their expected biological lifespan is not persuasive”.
C O N C L U S I O N
For the endovascular treatment of aortic arch pathology, 
the various technological new entities in pair to previously 
applied methods should be studied further in multicenter 
prospective randomized trials in order to create a safe thera-
peutic environment.
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